KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
3.6300
+0.5800 (+19.02%)
As of 12:01PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.0500
Open3.2300
Bid3.61 x 0
Ask3.62 x 0
Day's Range3.1700 - 3.7500
52 Week Range0.8700 - 3.7500
Volume2,898,893
Avg. Volume858,416
Market Cap276.225M
Beta (3Y Monthly)3.15
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • CNW Group2 hours ago

    IIROC Trading Halt - KHRN

    VANCOUVER , Feb. 19, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Khiron Life Sciences Corp. TSX-Venture Symbol: KHRN Reason: Single Stock Circuit Breaker Halt Time (ET): 10:13:39:436 ...

  • CNW Group2 hours ago

    IIROC Trading Resumption - KHRN

    VANCOUVER , Feb. 19, 2019 /CNW/ - Trading resumes in: Company: Khiron Life Sciences Corp. TSX-Venture Symbol: KHRN Resumption (ET): 10:18:39 IIROC can make a decision to impose a temporary suspension (halt) ...

  • ACCESSWIRE5 days ago

    Top 3 Cannabis Stocks Higher on Colombian Growth Story

    HOUSTON, TX / ACCESSWIRE / February 14, 2019 / Colombia is just beginning to transform itself into a multi-billion-dollar cannabis producer for the pharmaceutical industry. "Colombia is wooing foreign investors, talking up its potential in the new era of peace as a resource-rich country with a business-friendly regulatory environment," noted The Globe and Mail. Blueberries Medical Corp. (BBM), for example, just entered into a letter of intent for a joint venture with Harmony and Life S.A.S., operating as El Manantial medical centers.

  • GlobeNewswire11 days ago

    Branding Becomes Key as CBD is Expected to Overtake the Cannabis Market

    Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot reporting on the CBD market As it grows, branding becomes essential to companies hoping to stand out. According to Brightfield Group analysts, the CBD market is expected to hit $22 billion by 2022, overtaking the cannabis market with $20 billion by 2020. This is good news for most companies in the sector, but it also adds to market saturation, which means brand awareness may be the only way to stay ahead of the pack.

  • Do Institutions Own Khiron Life Sciences Corp. (CVE:KHRN) Shares?
    Simply Wall St.12 days ago

    Do Institutions Own Khiron Life Sciences Corp. (CVE:KHRN) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! A look at the shareholders of KhironRead More...

  • CNW Group13 days ago

    Khiron Life Sciences announces upsize of previously announced bought deal equity financing to $25 million

    VANCOUVER, Feb. 6, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, and including Cormark Securities Inc. (together, the "Underwriters"), to increase the size of its previously announced "bought deal" financing from $20,020,000 to $25,080,000 (the "Offering"). Pursuant to the amended terms, the Underwriters have agreed to purchase 11,400,000 common shares of the Company ("Common Shares"), on a "bought deal" basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per Common Share of $2.20 (the "Issue Price").

  • CNW Group13 days ago

    Khiron Life Sciences Enters Into $20 Million Bought Deal Equity Financing

    VANCOUVER, Feb. 6, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, and including Cormark Securities Inc. (together, the "Underwriters") under which the Underwriters have agreed to purchase 9,100,000 common shares of the Company ("Common Shares"), on a "bought deal" basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per Common Share of $2.20 (the "Issue Price") for gross proceeds of $20,020,000 (the "Offering"). The Company has also granted the Underwriters an over-allotment option (the "Over-Allotment Option") to purchase up to an additional 15% of the Common Shares at the Issue Price, exercisable in whole or in part at any time on or up to 30 days following the closing of the Offering.

  • CNW Group19 days ago

    Reminder: Dixie Brands and Khiron Life Sciences to Host Investor Call

    DENVER and TORONTO , Jan. 31, 2019 /CNW/ - Dixie Brands Inc. (" Dixie ") (CSE: DIXI.U), (Frankfurt : 0QV), one of the cannabis industry's leading consumer packaged goods companies, and Khiron ...

  • Transformative Joint Venture Between Dixie Brands and Khiron Life Sciences Brings a Portfolio of Highly Recognized Cannabis-Infused Products to Latin America and Khiron's Kuida® Cosmeceutical Brand to the Federally legal U.S. CBD Cosmetic Market
    CNW Group20 days ago

    Transformative Joint Venture Between Dixie Brands and Khiron Life Sciences Brings a Portfolio of Highly Recognized Cannabis-Infused Products to Latin America and Khiron's Kuida® Cosmeceutical Brand to the Federally legal U.S. CBD Cosmetic Market

    Establishes Khiron as Latin America's CPG leader with the addition of over 100 product SKUs across 15 categories immediately available to commercialize into Latin American pharmacies and retail outlets ...

  • CNW Group25 days ago

    Khiron Life Sciences Signs Binding LOI to Acquire 100% of NettaGrowth, Securing the First Medical THC and CBD Cannabis Licence and Cultivation Capacity in Uruguay, and Entry to the Brazilian Market

    TORONTO, Jan. 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Latin America, announced today that the Company has entered into a binding letter agreement dated January 24, 2019 to acquire 100% of NettaGrowth International Inc. ("NettaGro"), an arm's length party, which will own, at the time of completion of the transaction, all the outstanding shares of Dormul S.A. (doing business as Cannapur). Dormul has obtained the first licence to produce medical cannabis with THC for commercialization in Uruguay.

  • CNW Group25 days ago

    Live Investor Conference & Webinar: Cannabis Industry Companies Present January 30

    Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Jan. 25, 2019 /CNW/ -- Virtual Investor Conferences and KCSA Strategic Communications today ...

  • CNW Group29 days ago

    Khiron Life Sciences Expands to Second Latin America Cultivation Jurisdiction on Closing of Agreement with Dayacann to Enter Chilean Medical Cannabis Market

    TORONTO, Jan. 21, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has closed the previously announced MOU with Dayacann, holder of Chile's first medical cannabis cultivation license. As the dominant medical cannabis company in Latin America, this agreement expands on Khiron's multi jurisdiction cultivation strategy, securing access to cannabis cultivation for the Company's use in Chile, participation in clinical trials, and access to commercialize products to meet the needs of a market of 1.8 Million patients across the country.

  • CNW Grouplast month

    Khiron Life Sciences Launches Latin American Medical Education Program With Events in Colombia and Mexico

    TORONTO, Jan. 18, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has launched its Latin America medical education program with a schedule of doctor training and learning events in Bogota, Colombia on January 21-23, and in Mexico City, Mexico on February 28.

  • CNW Grouplast month

    Khiron Life Sciences Announced as Co-Host of Cannamexico World Summit 2019

    TORONTO, Jan. 17, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company will co-host Cannamexico World Summit 2019, a comprehensive cannabis symposium taking place April 25 - 26 at Centro Fox, Guanajuato, Mexico. This is the second annual Cannamexico event and is recognized as the first of its kind cannabis summit in Mexico. Companies in the fields of science, research, finance, medicine, government, technology, innovation, agro-industry and entrepreneurship, among others, will participate at the event in open discussions about medical cannabis.

  • CNW Grouplast month

    Khiron Life Sciences to Present as Lead Sponsor in First CannaTech Panama Global Medical Cannabis Summit

    TORONTO, Jan. 11, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company will be title sponsor of the first Cannatech Panama summit taking place February 12-13 in Panama City, Panama. Khiron will be prominently featured throughout the summit and key members of the Company's senior medical and compliance team will deliver session presentations on global medical cannabis patient, research and compliance topics with particular impact in Latin America.

  • CNW Group2 months ago

    Khiron Life Sciences Added to Horizons Marijuana Life Sciences Index ETF

    TORONTO, Dec. 31, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has been added to the Horizons Marijuana Life Sciences Index ETF ("HMMJ:TSX"), marking the Company's elevation to the senior index of publicly traded North American companies with significant business activity in the cannabis industry.

  • GlobeNewswire2 months ago

    Uptick Newswire Hosts Khiron Life Sciences Corp.’s President to Discuss the Growing Latin American Cannabis Market and How They Have Positioned Themselves as a Leader

    “Khiron is positioned to be the dominant integrated medical cannabis company in Latin America,” Naprawa said as he started the interview. Naprawa went on to say they’ve been at this for two years and have assembled an elite group of people and have a $75 million market share cap.

  • GlobeNewswire2 months ago

    Khiron Life Sciences Completes Acquisition of ILANS

    TORONTO, Dec. 13, 2018 -- Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with.

  • Baystreet2 months ago

    Stocks in play: Khiron Life Sciences Corp

    Has signed an endorsement agreement with the highly respected and influential Colombian Association ...

  • CNW Group2 months ago

    Khiron Life Sciences Receives Endorsement from Prominent Colombian Medical Association for the Study of Pain

    TORONTO, Dec. 11, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, is pleased to announce it has signed an endorsement agreement with the highly respected and influential Colombian Association for the Study of Pain (ACED). In endorsing Khiron's patient-focused approach to medical cannabis research and product development, ACED has committed to partnering with the Company on a schedule of patient and physician education programs, modules and events.

  • Market Exclusive3 months ago

    Khiron Life Nears Launching Nutraceutical Products in Mexico

    Medical cannabis firm Khiron Life Sciences (OTCQB: KHRNF) announced that its subsidiary Kuida Life Mexico S.A. received approval from Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) to import and commercialize three products of the company’s Nutraceutical Line. The approved initial products include; a CBD (cannabidiol) based formulation designed to help promote sleep; […] The post Khiron Life Nears Launching Nutraceutical Products in Mexico appeared first on Market Exclusive.